Europe Molecular Oncology Diagnostics Market to Reach $1.52 Billion by 2033, Driven by Digital Health Integration, Real-Time Genetic Data Use, and Expanding Applications in Precision Cancer Care.

The European molecular oncology diagnostics market is projected to grow at a CAGR of 10.78% from $606.0 million in 2024 to $1.52 billion by 2033. The market is driven by technological advancements, increasing cancer incidence, and better patient outcomes. However, high costs and a lack of qualified personnel remain challenges. Despite these, the market is expected to grow due to efforts to standardize payment regulations, lower test prices, and increase clinician genomic literacy.

The European molecular oncology diagnostics market is projected to grow at a compound annual growth rate (CAGR) of 10.78%, rising from $606.0 million in 2024 to $1.52 billion by 2033 [1]. This growth is fueled by technological advancements, increasing cancer incidence, and better patient outcomes. Key drivers include the expansion of next-generation sequencing (NGS) panels, the growth of liquid biopsy adoption, and the integration of molecular diagnostics with immuno-oncology treatments.

Technological advancements, such as NGS and digital PCR, are significantly driving market growth. These technologies enable broader genomic profiling and earlier detection of cancer, leading to more accurate treatment choices and better patient outcomes. Additionally, the rising cancer incidence in Europe, coupled with an aging population, is increasing demand for precision diagnostic tools [1].

Despite these positive factors, the market faces several challenges. High costs associated with molecular diagnostic testing remain a significant barrier, particularly in Central and Eastern Europe with limited healthcare budgets. Furthermore, the lack of qualified personnel to operate sophisticated diagnostic tools and interpret complex genomic data hampers market penetration [1].

To overcome these challenges, cooperative efforts among biotech companies, pharmaceutical companies, diagnostic producers, and academic research centers are accelerating innovation. Standardizing payment regulations, lowering test prices, and increasing clinician genomic literacy are essential for unlocking the full potential of molecular diagnostics in cancer management across various European healthcare systems [1].

Market segmentation by cancer type includes solid tumors and hematologic malignancies, with hospitals and diagnostic centers being the primary end users. Key players in this market include Biocartis Group NV, bioMerieux, F. Hoffmann-La Roche Ltd, and QIAGEN N.V. [1].

In addition to market trends, Hutchmed (NASDAQ: HCM) has completed patient enrollment for the SANOVO Phase III trial, evaluating the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutation and MET overexpression in China [2]. The trial's primary endpoint is progression-free survival (PFS), with secondary endpoints including overall survival, objective response rate, and safety measures. Topline results are expected in the second half of 2026, potentially leading to a supplementary New Drug Application to China's NMPA.

In conclusion, the European molecular oncology diagnostics market is poised for significant growth, driven by technological advancements and increasing demand for precision medicine. Addressing challenges related to cost and personnel will be crucial for realizing the full potential of this market.

References:
[1] https://www.businesswire.com/news/home/20250820589249/en/Europe-Molecular-Oncology-Diagnostics-Market-Research-Report-2024-2033-Digital-Health-Integration-Real-Time-Genetic-Data-Use-and-Expanding-Applications-in-Precision-Cancer-Care-Fuel-Growth---ResearchAndMarkets.com
[2] https://www.stocktitan.net/news/HCM/hutchmed-completes-patient-enrollment-of-sanovo-phase-iii-trial-of-nkqd13baflno.html